Cannabinoid Receptors (Cannabinoid Receptor)

A class of G-protein-coupled receptors that are specific for CANNABINOIDS such as those derived from CANNABIS. They also bind a structurally distinct class of endogenous factors referred to as ENDOCANNABINOIDS. The receptor class may play a role in modulating the release of signaling molecules such as NEUROTRANSMITTERS and CYTOKINES.

Also Known As:

Networked: 1133 relevant articles (41 outcomes, 157 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Di Marzo, Vincenzo: 23 articles (11/2014 - 03/2002)
2.	Cravatt, Benjamin F: 18 articles (11/2015 - 04/2004)
3.	Maccarrone, Mauro: 18 articles (10/2015 - 07/2004)
4.	Mackie, Ken: 18 articles (05/2015 - 12/2006)
5.	Zimmer, Andreas: 16 articles (08/2015 - 04/2005)
6.	Guzmán, Manuel: 16 articles (06/2015 - 01/2003)
7.	Lutz, Beat: 15 articles (10/2015 - 04/2004)
8.	Bifulco, Maurizio: 14 articles (06/2015 - 03/2002)
9.	Lichtman, Aron H: 13 articles (05/2015 - 06/2004)
10.	Piomelli, Daniele: 11 articles (10/2014 - 12/2002)

Related Diseases

1.	Pain (Aches) 04/01/2004 - "From a historical perspective to the present day, all the evidence suggests that activation of cannabinoid receptors (CBRs) is beneficial for gut discomfort and pain, which are symptoms related to dysmotility and visceral perception. " 01/01/2014 - "In particular, cannabinoid receptor 2 (CB2) has emerged as an attractive target for management of chronic pain, as demonstrated in several studies with inflammatory and neuropathic preclinical pain models. " 08/01/2011 - "This study clearly shows that atypical cannabinoid receptors are involved in joint nociception and these novel targets may be advantageous for the treatment of inflammatory pain." 03/31/2009 - "Pharmacological studies have indirectly shown the possible presence of cannabinoid receptors in the urinary bladder and their potential role in reducing bladder inflammatory pain. " 10/20/2015 - "We show that anxiolysis depends on intact cannabinoid receptor 1 (CB1) receptors on forebrain GABAergic neurons and pain reduction on activation of peripheral CB1 and CB2 receptors. "
2.	Obesity 09/23/2008 - "Cannabinoid receptor type 1 (CB1) antagonists show promise in the treatment of obesity and its metabolic consequences. " 04/01/2012 - "In this study we analysed the effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist with poor brain penetration, in an animal model of diet-induced obesity. " 12/01/2011 - "The objective of this study was to assess the safe use of LY2190416, a cannabinoid receptor 1 receptor antagonist/inverse agonist, for obesity management in dogs. " 01/01/2011 - "In vitro studies indicate a regulatory role for the cannabinoid receptor 1 (CB1) in adipocyte function and CB1-receptor deficient (CB1-/-) mice are resistant to high fat diet-induced obesity. " 01/01/2008 - "Different studies have investigated the relationship between polymorphisms of the cannabinoid receptor 1 (CNR1) gene and obesity with conflicting results. "
3.	Neuralgia (Stump Neuralgia) 12/31/2002 - "These studies provide insight into the functional roles of cannabinoid receptor subtypes, CB1 and CB2, in cannabinoid antinociceptive mechanisms as revealed in animal models of acute and persistent (somatic inflammatory, visceral inflammatory, neuropathic) pain. " 01/01/2016 - "Thus, dual FAAH/MAGL inhibition may have greater potential in alleviating neuropathic pain, compared with selective FAAH and MAGL inhibitors, or cannabinoid receptor agonists." 01/01/2016 - "Cannabinoid receptor agonists have good efficacy in animal models of neuropathic pain; they have a poor therapeutic window. " 10/01/2015 - "Cannabinoid receptor type 2 (CB2) agonists display potential analgesic effects in acute and neuropathic pain. " 05/01/2015 - "Cannabinoid receptor agonists are moderately effective at reducing neuropathic pain but are limited by psychoactivity. "
4.	Hyperalgesia 09/26/2012 - "The results suggest that the mechanical and thermal hyperalgesia observed following BPA in mice is dependent on cannabinoid receptors. " 01/01/2012 - "SA daily treatment significantly reduced mechanical allodynia in KOR and cannabinoid receptor 1 (CB1R) sensitive manner. " 02/01/2011 - "Chronic WA stress was associated with visceral hyperalgesia in response to colorectal distension, increased stool output and reciprocal changes in cannabinoid receptor 1 (CB1) (decreased) and TRPV1 (increased) receptor expression and function. " 09/01/2009 - "Direct-acting cannabinoid receptor agonists are well known to reduce hyperalgesic responses and allodynia after nerve injury, although their psychoactive side effects have damped enthusiasm for their therapeutic development. " 02/01/2009 - "We investigated whether cannabinoid receptor 1 (CB1) and vanilloid receptor 1 (TRPV1; transient receptor potential vanilloid 1) are involved in stress-induced visceral hyperalgesia. "
5.	Parkinson Disease (Parkinson's Disease) 11/01/2002 - "Thus, cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson's disease." 06/01/2001 - "The data support the idea that cannabinoid receptor antagonists may provide a useful treatment for the symptoms of Parkinson's disease." 04/05/2010 - "This study sought to determine if expression of the CB(1) subtype of cannabinoid receptor is altered in the two most commonly used rat models of Parkinson's disease. " 12/01/2013 - "Recent evidence suggests that the blockade of cannabinoid receptors might be beneficial to alleviate motor deficits observed in Parkinson's disease. " 01/01/2013 - "The CB1 cannabinoid receptors are abundantly expressed in the basal ganglia, the circuitry that is mostly affected in Parkinson's Disease (PD). "

Related Drugs and Biologics

1.	rimonabant
2.	Cannabinoids
3.	Endocannabinoids (Endocannabinoid)
4.	Win 55212-2 (WIN 55,212)
5.	Ligands
6.	CB1 Cannabinoid Receptor (CB1 Receptor)
7.	anandamide (arachidonylethanolamide)
8.	Tetrahydrocannabinol (THC)
9.	HU 211 (HU 210)
10.	methanandamide

Related Therapies and Procedures

1.	Electroacupuncture
2.	Ligation
3.	Therapeutics
4.	Analgesia
5.	Drug Therapy (Chemotherapy)